Michelson Diagnostics develops, manufactures and markets the VivoSight multi-beam Optical Coherence Tomography (OCT) scanner, a point-of-care, real-time tissue imaging device that provides continuous images of the epidermis and superficial dermis. The company holds CE and TGA regulatory clearances and has FDA 510(k) approval in the United States. It plans to use new funding to expand its commercial presence in Germany and to launch the VivoSight OCT system more broadly. Ongoing clinical work includes a US multi-centre clinical biopsy avoidance study the company intends to complete. Michelson is exploring further applications of the VivoSight system in wound care and dentistry. The company was founded in 2006, is led by Chairman Brian Howlett, has 18 employees and maintains offices in Germany and the USA. Michelson Diagnostics develops multi-beam Optical Coherence Tomography technology using an advanced laser scanner to produce high-resolution images of tissue. Its core product, the VivoSight OCT system, is focused on non-invasive diagnosis and monitoring of cutaneous and epithelial conditions including non-melanoma skin cancer (NMSC). The VivoSight system has regulatory clearance in Europe, the USA and Australia for use by trained clinicians. The company plans to expand VivoSight sales in Germany, develop a second-generation VivoSight with enhanced functionality, and initiate US market access with a planned pilot clinical study. Michelson Diagnostics was founded in 2006 and is led by CEO Jon Holmes; it currently has 18 employees and sales offices in Germany and the USA. The company is based in Orpington, Kent, UK. Michelson Diagnostics is a Kent, UK-based medical device company that has developed and brought to market the VivoSight scanning device for non-melanoma skin cancer. The VivoSight scanner enables clinicians to see under the skin surface in real time to help decide whether to treat a lesion, which treatment to use, and to map how far a tumour has spread so surgery can conserve healthy tissue. Led by CEO Jon Holmes, the company has an installed base of VivoSight skin cancer laser scanners and is expanding commercial operations. Michelson received a £607k investment as an extension to a £1.92M investment from October 2011. Backers on this round include existing shareholders Octopus Investments, Catapult Venture Managers and individual investors, including some London Business Angels which invested £332k. The company intends to use the proceeds to expand sales and support infrastructure in the USA and Europe to support its growing installed base. Michelson Diagnostics develops multi-beam optical coherence tomography (OCT) instruments for dermatology, including its VivoSight scanner. The VivoSight is based on the company’s patented multi-beam OCT technology and allows dermatologists to see below the surface of the skin to gather clinical information. The scanner has CE and FDA regulatory clearance and has entered commercial service at dermatology clinics in the USA and Germany. Founded in 2006 and led by CEO Jon Holmes, the company is based in Kent, England, with US operations in South Dartmouth, Massachusetts. In November 2011 it received a £1.912m investment to expand sales and support infrastructure in the USA and Europe. Backers include Octopus Investments, Catapult Venture Managers and individual investors from London Business Angels. Michelson Diagnostics, based in Orpington, UK, has developed a laser scanning technology to image skin and other surface tissue at much higher resolution. Its core product, the VivoSight scanner, enables clinicians to see beneath the skin in real time to inform treatment decisions and assess tumour spread so surgery can conserve healthy tissue. The device has won CE and FDA regulatory clearance for clinical use in Europe and the USA and is being evaluated by skin cancer specialists at their clinics. The company received a second investment of £300k from Octopus Investments, adding to an initial £1.7M investment in October 2010. The £300k is intended to fund scanner manufacturing and to grow sales infrastructure in the UK and USA. The disclosed funding from these investments is roughly £2.0M to support product commercialization and sales expansion.

Total raised

$13M

Funding rounds

6

Latest round

Series B

Latest activity

Feb 2015